13F-HR filed by Canaan Partners XI LLC
Canaan Partners XI LLC filed this 13F-HR for the quarter ended 2022-12-31, filed 2023-02-01, with 6 holding rows worth $127,350,603.
- Accession
- 0000950123-23-000621
- Filer
- CIK 1850694
- Filed
- 2023-02-01
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2022
A holdings report, 5 entries on the cover page, a total value of $127,350,603 stated on the cover page (in dollars after the unit check, H1), rows summing to $127,350,603 with VALUE read as dollars as filed, 13F file number 028-21580. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| Day One Biopharmaceuticals Inc | 23954D109 | Common Stock | 2,548,403 | $54,841,633 | dollars as filed | |
| TYRA BIOSCIENCES INC | 90240B106 | COMMON STOCK | 4,409,991 | $33,515,932 | dollars as filed | |
| AEVA TECHNOLOGIES INC | 00835Q103 | COM | 18,485,197 | $25,139,868 | dollars as filed | |
| RALLYBIO CORP | 75120L100 | COM | 2,059,712 | $13,532,308 | dollars as filed | |
| VECTIVBIO HLDG AG | H9060V101 | COM | 37,051 | $320,862 | dollars as filed | |
| BRIDGEBIO PHARMA INC | 09077J107 | COM | 0 | $0 | dollars as filed | Value filed as zero, left out of ratios.Amount filed as zero, left out of ratios. |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000950123-23-000621 | this filing | 2023-02-01 | acceptance time not in the bulk data set |